Compare CEPU & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CEPU | ZYME |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2017 | 2022 |
| Metric | CEPU | ZYME |
|---|---|---|
| Price | $14.11 | $24.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $17.50 | ★ $38.90 |
| AVG Volume (30 Days) | 300.0K | ★ 621.3K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $10.11 | $183.10 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $7.43 | $11.86 |
| 52 Week High | $18.50 | $29.75 |
| Indicator | CEPU | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 51.68 |
| Support Level | $13.82 | $22.25 |
| Resistance Level | $16.53 | $27.81 |
| Average True Range (ATR) | 0.62 | 0.90 |
| MACD | -0.09 | 0.13 |
| Stochastic Oscillator | 9.82 | 67.09 |
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.